TAK-024

TAK-024 is a platelet inhibitor with IC50s of 31, 79 and 51 nM in human, monkey and guinea pig, respectively.

Signaling Pathways >> GPCR/G Protein >> P2Y Receptor

Research Areas >> Cardiovascular Disease

IC50: 31 nM (human platelet), 79 nM (monkey platelet), 51 nM (pig platelet)[1]

TAK-024 is a platelet inhibitor with IC50s of 31, 79 and 51 nM in human, monkey and guinea pig, respectively. In a preliminary experiment, the IC50 value of TAK-024 in the heparinized blood sample is 230 nM, 4.5-fold less potent than that in the citrated physiological blood sample. The ID50 value of TAK-024 on ex vivo ADP-induced platelet aggregation in guinea pigs is 0.18 μg/kg/min, the dissociation ratio of TAK-024 is found to be 32[1].

Intravenous infusion of TAK-024 (compound 12c) at 1.6 μg/mL/min completely prevents arterial thrombus formation induced by endothelial injury in guinea pigs. Results demonstrate the inhibitory effects of TAK-024 on the carotid thrombosis induced by balloon injury in guinea pigs and the ID50 value is 0.73 μg/kg/min. A single dose of TAK-024 at 100 μg/kg iv produces almost complete inhibition for 120 min, and about 40% inhibition is observed after 240 min. Dose-dependent inhibition of platelet aggregation is achieved with a single iv dose of 30 to 100 μg/kg of TAK-024[1].

Blood is collected from guinea pigs and used in this study. Blood is withdrawn into a plastic syringe containing 3.8% (human and monkey) or 3.15% (guinea pig) sodium citrate (1:10 citrate/blood, v/v). Platelet rich plasma (PRP) and platelet poor plasma (PPP) are obtained by centrifugation at 1000 g for 3 to 5 s and 1000 g for 20 min at room temperature, respectively. PRP (250 μL), in a cuvette stirred at 1000 rpm, is prewarmed for 2 min at 37°C with variousconcentrations of TAK-024 (25 μL). The change in light transmittance is measured after the addition of aggregating agents (25 μL) to the cuvette[1].

Male guinea pigs (250 to 400 g) are used in this study. TAK-024 is given as continuous iv infusions, and the vehicle is given to the control animals. Ninety minutes after starting the infusion, citrated blood is collected from the abdominal aorta under anesthesia, and Platelet rich plasma (PRP) is prepared. As the aggregation inducer, ADP (20 μL, submaximal concentration) is used. The bleeding time (BT) is also examined 90 min after starting the infusion[1].

[1]. Kitamura S, et al. Potent dibasic GPIIb/IIIa antagonists with reduced prolongation of bleeding time: synthesis and pharmacological evaluation of 2-oxopiperazine derivatives. J Med Chem. 2001 Jul 19;44(15):2438-50.

Suramin sodium | MRS 2578 | Diquafosol Tetrasodium | Prasugrel | BPTU | AZD 1283